[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1968601T3 - Salte af kalium-ATP-kanalåbnere og anvendelser heraf - Google Patents

Salte af kalium-ATP-kanalåbnere og anvendelser heraf

Info

Publication number
DK1968601T3
DK1968601T3 DK06847875.9T DK06847875T DK1968601T3 DK 1968601 T3 DK1968601 T3 DK 1968601T3 DK 06847875 T DK06847875 T DK 06847875T DK 1968601 T3 DK1968601 T3 DK 1968601T3
Authority
DK
Denmark
Prior art keywords
salts
applications
atp channel
channel openers
outcomes
Prior art date
Application number
DK06847875.9T
Other languages
English (en)
Inventor
Neil M Cowen
Kenneth B Kashkin
Khaled A Yamout
Original Assignee
Essentialis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Essentialis Inc filed Critical Essentialis Inc
Application granted granted Critical
Publication of DK1968601T3 publication Critical patent/DK1968601T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
DK06847875.9T 2006-01-05 2006-12-20 Salte af kalium-ATP-kanalåbnere og anvendelser heraf DK1968601T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75694106P 2006-01-05 2006-01-05
US85474006P 2006-10-27 2006-10-27
PCT/US2006/048711 WO2007081521A2 (en) 2006-01-05 2006-12-20 Salts of potassium atp channel openers and uses thereof

Publications (1)

Publication Number Publication Date
DK1968601T3 true DK1968601T3 (da) 2012-02-06

Family

ID=38256790

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06847875.9T DK1968601T3 (da) 2006-01-05 2006-12-20 Salte af kalium-ATP-kanalåbnere og anvendelser heraf

Country Status (13)

Country Link
US (11) US7799777B2 (da)
EP (3) EP2404604B1 (da)
JP (1) JP5543110B2 (da)
CN (2) CN101868239B (da)
AT (1) ATE529113T1 (da)
AU (1) AU2006335153B2 (da)
CA (1) CA2636274C (da)
DK (1) DK1968601T3 (da)
ES (2) ES2374963T3 (da)
HK (1) HK1117078A1 (da)
HR (1) HRP20120005T1 (da)
PL (1) PL1968601T3 (da)
WO (1) WO2007081521A2 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
EP1781265B1 (en) * 2004-08-25 2010-04-07 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
ATE529113T1 (de) 2006-01-05 2011-11-15 Essentialis Inc Salze von kalium-atp-kanal-öffnern und ihre verwendungen
JP5271918B2 (ja) * 2007-01-16 2013-08-21 アイピントゥル，エルエルシー メタボリック症候群治療用の新規組成物
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
US20090062264A1 (en) * 2007-07-02 2009-03-05 Cowen Neil M Salts of potassium atp channel openers and uses thereof
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
US20090177142A1 (en) 2008-01-09 2009-07-09 Smiths Medical Md, Inc Insulin pump with add-on modules
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
CA2666036C (en) * 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
US20100120906A1 (en) * 2008-07-18 2010-05-13 Valeant Pharmaceuticals International Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
WO2010033878A2 (en) 2008-09-19 2010-03-25 David Brown Solute concentration measurement device and related methods
US20120053172A1 (en) * 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
JP2012520883A (ja) * 2009-03-16 2012-09-10 アイピントゥル，エルエルシー アルツハイマー病及び骨粗鬆症の治療並びに老化の軽減
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
CA2769030C (en) 2009-07-30 2016-05-10 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
WO2013004249A1 (en) 2011-07-05 2013-01-10 Concit Pharma Aps The use of serotonin receptor agonists for treatment of movement disorders
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US10201656B2 (en) 2013-03-13 2019-02-12 Tandem Diabetes Care, Inc. Simplified insulin pump for type II diabetics
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9492608B2 (en) 2013-03-15 2016-11-15 Tandem Diabetes Care, Inc. Method and device utilizing insulin delivery protocols
EP3217963B1 (en) * 2014-11-14 2020-05-20 Essentialis, Inc. Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
CN107638569A (zh) * 2016-07-21 2018-01-30 上海聿健生物科技有限公司 增强褐色脂肪细胞产热效率的方法和应用
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
US10780068B2 (en) 2017-05-05 2020-09-22 Nino Sorgente Methods and compositions for improving eye health
CN111954966A (zh) 2018-04-10 2020-11-17 坦德姆糖尿病护理股份有限公司 用于对医疗设备进行感应充电的系统和方法
EP3801482A4 (en) * 2018-05-25 2022-06-29 The Children's Medical Center Corporation Methods for treating spinal cord injury
CN111888330B (zh) * 2020-09-18 2022-08-16 常州市第四制药厂有限公司 一种二氮嗪口服混悬溶液及制备方法
CN113274538B (zh) * 2021-05-28 2022-09-06 中国科学院过程工程研究所 一种具有创面主动修复功能的bFGF缓释纳米敷料及其制备方法和应用
CN116236451B (zh) * 2023-04-18 2024-04-19 淄博市中心医院 一种阿卡波糖片、制备方法及用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3112307A (en) * 1963-11-26 Derivatives of benzothiadiazine
US3269906A (en) * 1966-08-30 Imino-j,x-dihydro-l,z,x-benzothiadiazine- i,i-dioxides
US2678311A (en) * 1952-05-07 1954-05-11 Delmar Chem Theophylline salts
US3057862A (en) * 1959-03-25 1962-10-09 Olin Mathieson Benzothiadiazine derivatives
US2956573A (en) * 1959-06-01 1960-10-18 Brown Rutherford Automobile windshield cover
US2986573A (en) 1961-01-18 1961-05-30 Schering Corp Method for the treatment of hypertension
GB982072A (en) 1960-09-19 1965-02-03 Scherico Ltd Benzothiadiazine-1,1-dioxides and processes for their manufacture
US3287360A (en) * 1960-12-27 1966-11-22 Merck & Co Inc 3-carboxy-benzothiadiazine derivatives
US3304228A (en) * 1961-06-26 1967-02-14 Schering Corp Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides
US3265573A (en) * 1962-07-27 1966-08-09 Squibb & Sons Inc Benzothiadiazinesulfonamide-1, 1-dioxide composition
US3345365A (en) * 1964-03-31 1967-10-03 Schering Corp Novel 1, 2, 4-benzothiadiazine-1, 1-dioxide derivatives
US3431138A (en) 1967-07-14 1969-03-04 American Cyanamid Co Method for coating pharmaceutical forms with methyl cellulose
US4029780A (en) * 1974-10-29 1977-06-14 Dainippon Pharmaceutical Co., Ltd. 3-Piperazinyl 1,2,4-benzothiadiazine 1,1-dioxide derivatives their compositions and method of use
JPS5248889A (en) 1975-10-16 1977-04-19 Inoue Japax Res Inc Electrolytic grinding grindstone
JPS5278889A (en) * 1975-12-25 1977-07-02 Dainippon Pharmaceut Co Ltd Preparation of 3-(4-methyl-1-piperazinyl)-2h-benzothiadiazine-1,1-oxid e derivatives
US4184039A (en) * 1977-12-01 1980-01-15 Paul Finkelstein Benzothiadiazine 1, 1-dioxides
DE2757925A1 (de) 1977-12-24 1979-06-28 Bayer Ag Diazacyclo-1.2.4-benzothiadizine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
JPS5995212A (ja) 1982-11-23 1984-06-01 Nitto Electric Ind Co Ltd 基剤組成物及び外用医薬組成物
DE3530857A1 (de) 1985-08-29 1987-03-05 Hoechst Ag Verfahren zur herstellung von niedrigviskosen celluloseethern
GB8601204D0 (en) 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
DE68917946T2 (de) 1988-01-29 1995-01-05 Peter H Proctor Haarwachstumanregung mit Nitroxyd und anderen Radikalen.
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US6361795B1 (en) * 1989-09-05 2002-03-26 Alza Corporation Method for lowering blood glucose
US5284845A (en) 1991-03-14 1994-02-08 Paulsen Elsa P Use of oral diazoxide for the treatment of disorders in glucose metabolism
US5252338A (en) 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
FR2690160A1 (fr) 1992-04-15 1993-10-22 Rhone Poulenc Rorer Sa Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant.
US5378704A (en) * 1992-04-15 1995-01-03 E. R. Squibb & Sons, Inc. Non-peptidic angiotensin-II-receptor-antagonists
US5356775A (en) * 1992-07-29 1994-10-18 Brigham & Women's Hospital Primary structure for functional expression from complementary DNA of a mammalian ATP-sensitive potassium channel
US5629045A (en) 1992-09-17 1997-05-13 Richard L. Veech Biodegradable nosiogenic agents for control of non-vertebrate pests
US5376384A (en) 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
FR2703051B1 (fr) 1993-03-26 1995-04-28 Adir Nouvelles pyridothiadiazines, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
US5747278A (en) * 1993-05-21 1998-05-05 California Institute Of Technology DNA encoding inward rectifier, G-protein activated, mammalian, potassium KGA channel and uses thereof
US5965620A (en) 1993-07-23 1999-10-12 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
EP0705298B1 (en) * 1993-12-01 2002-03-27 Bioartificial Gel Technologies Inc. Albumin based hydrogel
AU1839695A (en) * 1994-02-08 1995-08-29 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Dna encoding atp-sensitive potassium channel proteins and uses thereof
US5399359A (en) 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
WO1996041616A1 (en) 1995-06-09 1996-12-27 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US6225310B1 (en) * 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
US6309855B1 (en) * 1996-02-08 2001-10-30 Centre National De La Recherche (Cnrs) Family of mammalian potassium channels, their cloning and their use, especially for the screening of drugs
US7122515B2 (en) * 1996-05-17 2006-10-17 Pharmacia Ab Methods for treating a patient having Metabolic Syndrome
AU4133997A (en) 1996-09-12 1998-04-02 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
CA2309597A1 (en) * 1997-11-10 1999-05-20 Hiroshi Sorimachi Sustainedly releasing agents for medicines and sustainedly released medicinal compositions containing the same
AU5134699A (en) 1998-07-24 2000-02-14 Andrix Pharmaceuticals, Inc. Granule modulating hydrogel system
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197976B1 (en) * 1998-12-14 2001-03-06 Syntex (U.S.A.) Llc Preparation of ketorolac
AU764921B2 (en) * 1998-12-14 2003-09-04 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6329367B1 (en) * 1998-12-18 2001-12-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
PT1140187E (pt) * 1998-12-23 2004-01-30 Searle Llc Combinacoes de um inibidor de ibat e de um inibidor de mtp para indicacoes cardiovasculares
US6197765B1 (en) * 1999-06-08 2001-03-06 Pnina Vardi Use of diazoxide for the treatment of metabolic syndrome and diabetes complications
WO2001030332A2 (en) * 1999-10-22 2001-05-03 Wake Forest University Methods of protecting neuronal function
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2801587B1 (fr) * 1999-11-30 2002-01-11 Adir Nouveaux derives de benzothiadiazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE10012199A1 (de) 2000-03-13 2001-09-20 Haarmann & Reimer Gmbh Eingekapselte Substanzen mit kontrollierter Freisetzung
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
WO2002000223A1 (en) * 2000-06-26 2002-01-03 Novo Nordisk A/S Use of potassium channel agonists for reducing fat food comsumption
ATE320318T1 (de) 2000-06-30 2006-04-15 Ngimat Co Verfahren zur abscheidung von materialien
DE60123800T2 (de) * 2000-08-04 2007-10-11 Takeda Pharmaceutical Co. Ltd. Salze von benzimidazol-derivaten und deren verwendung
AU2002213174A1 (en) 2000-10-13 2002-04-22 Massaharu Akao Treatment of apoptotic cell death
GB0025473D0 (en) 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
WO2002050047A1 (en) 2000-12-20 2002-06-27 Glaxo Group Limited Substitued oxazoles and thiazoles as hppar alpha agonists
AU2002221577A1 (en) * 2000-12-21 2002-07-01 Novo-Nordisk A/S A new process for preparing fused 1,2,4-thiadiazine derivatives
AU2002226266A1 (en) * 2001-01-19 2003-10-08 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. Amine derivative with potassium channel regulatory function, its preparation and use
TW478039B (en) 2001-04-09 2002-03-01 Promos Technologies Inc Phase shift alignment system
WO2002088378A2 (en) * 2001-04-13 2002-11-07 Millennium Pharmaceuticals, Inc. 66784, a novel human potassium channel and uses therefor
DE10209979A1 (de) 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
AU2003248566A1 (en) 2002-05-24 2003-12-12 Smithkline Beecham Corporation Novel anti-infectives
WO2003103606A2 (en) 2002-06-10 2003-12-18 Metabolex, Inc. Methods and compositions for treating and diagnosing diabetes
WO2003105896A1 (en) 2002-06-14 2003-12-24 Novo Nordisk A/S Combined use of a modulator of cd3 and a beta cell resting compound
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US20040097492A1 (en) * 2002-11-01 2004-05-20 Pratt John K Anti-infective agents
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
US7902203B2 (en) * 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
US7311727B2 (en) 2003-02-05 2007-12-25 Board Of Trustees Of The University Of Arkansas Encased stent
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
US20040229803A1 (en) * 2003-04-22 2004-11-18 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
FR2854634B1 (fr) * 2003-05-05 2005-07-08 Servier Lab Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4220314B2 (ja) 2003-06-12 2009-02-04 株式会社テクノ菱和 装着型軟ｘ線検出器
US7378414B2 (en) * 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
EP1663239A4 (en) * 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
US20070254871A1 (en) * 2004-06-23 2007-11-01 Neurotec Pharma, S.L. Compounds for the Treatment of Inflammation of the Central Nervous System
EP1781265B1 (en) * 2004-08-25 2010-04-07 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
CN101043879A (zh) * 2004-08-25 2007-09-26 伊森舍丽斯有限公司 钾atp通道开放剂的药物制剂及其应用
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
FR2877338B1 (fr) * 2004-11-03 2007-01-26 Servier Lab Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20060263805A1 (en) * 2005-03-16 2006-11-23 Andre Terzic Diagnosing and treating potassium channel defects
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
ATE529113T1 (de) 2006-01-05 2011-11-15 Essentialis Inc Salze von kalium-atp-kanal-öffnern und ihre verwendungen
US20070254863A1 (en) * 2006-04-27 2007-11-01 Jochen Antel Use of CBx cannabinoid receptor modulators as potassium channel modulators
US8314175B2 (en) 2007-03-22 2012-11-20 The Nippon Synthetic Chemical Aqueous composition for recording medium, and ink-jet recording medium using the same
US20090062264A1 (en) * 2007-07-02 2009-03-05 Cowen Neil M Salts of potassium atp channel openers and uses thereof
WO2013130411A1 (en) 2012-02-27 2013-09-06 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
EP3217963B1 (en) 2014-11-14 2020-05-20 Essentialis, Inc. Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Also Published As

Publication number Publication date
US20130225806A1 (en) 2013-08-29
JP2010500960A (ja) 2010-01-14
CN103172592A (zh) 2013-06-26
US20130309301A1 (en) 2013-11-21
WO2007081521A3 (en) 2008-02-14
EP3545958A1 (en) 2019-10-02
EP1968601A2 (en) 2008-09-17
CA2636274A1 (en) 2007-07-19
PL1968601T3 (pl) 2012-03-30
EP1968601B1 (en) 2011-10-19
EP2404604A1 (en) 2012-01-11
CN101868239A (zh) 2010-10-20
US11786536B2 (en) 2023-10-17
US20170143732A1 (en) 2017-05-25
EP2404604B1 (en) 2019-02-06
US20190117665A1 (en) 2019-04-25
US7799777B2 (en) 2010-09-21
ES2374963T3 (es) 2012-02-23
CA2636274C (en) 2015-05-26
US20100256360A1 (en) 2010-10-07
US20220047605A1 (en) 2022-02-17
US9381202B2 (en) 2016-07-05
US10085998B2 (en) 2018-10-02
US11045478B2 (en) 2021-06-29
US20100028429A1 (en) 2010-02-04
ES2984297T3 (es) 2024-10-29
US20070191351A1 (en) 2007-08-16
EP1968601A4 (en) 2009-02-25
AU2006335153B2 (en) 2012-03-15
JP5543110B2 (ja) 2014-07-09
HRP20120005T1 (hr) 2012-01-31
US20200222417A1 (en) 2020-07-16
CN103172592B (zh) 2016-01-06
US20240252507A1 (en) 2024-08-01
US7572789B2 (en) 2009-08-11
HK1117078A1 (en) 2009-01-09
EP3545958B1 (en) 2024-07-10
WO2007081521A2 (en) 2007-07-19
CN101868239B (zh) 2015-06-10
US20090148526A1 (en) 2009-06-11
AU2006335153A1 (en) 2007-07-19
ATE529113T1 (de) 2011-11-15

Similar Documents

Publication Publication Date Title
DK1968601T3 (da) Salte af kalium-ATP-kanalåbnere og anvendelser heraf
DK1781265T3 (da) Farmaceutiske formuleringer af kalium ATP-kanal-åbnere og anvendelser deraf
MX2021003982A (es) Activador del canal de katp para usarse en el incremento de la masa muscular del miembro inferior en un sujeto que padece el síndrome de smith-magenis (sms).
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
DK3248600T3 (da) Kombinationer og måder til administration af terapeutiske stoffer og kombinationsterapi
TW200806289A (en) Sustained-release formulation of zonisamide
DK2043637T3 (da) Fremgangsmåder og medikamenter til administrering af ibuprofen
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
TW200833367A (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
NO20075199L (no) Treatment or prevention of pruritus
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
NO20075508L (no) Stannsoporfinpreparater og administrering
WO2007144889A3 (en) Treatment of neurofibromatosis
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
WO2007067753A3 (en) Methods of reducing side effects in cancer therapy
Nakajima Crawling sensation in an elderly patient: case report
Cosme Amoxicillin/clarithromycin/metronidazole/omeprazole
Huang Emotional lability and depression: case report
Barsotti CMV lung infection, bladder infection and erythematous rash: 3 case reports
RU2009112931A (ru) Способ лечения больных с переломом нижней челюсти
UA112970U (uk) Спосіб медичної реабілітації спортсменів силових видів спорту, які випробовують інтенсивні фізичні навантаження, з наявністю ознак імунодефіциту та ендогенної інтоксикації
RU2007135456A (ru) Способ лечения сахарного диабета 1-го типа